Drug Trial Radar · NCT05140863
To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Postherpetic Neuralgia
Last checked: Nov 20, 2026Latest source record: Feb 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
372
Actual
Start
Nov 1, 2021
Primary completion
Dec 22, 2022
Study completion Jan 5, 2023
Sponsor
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Investigate the Efficacy and Safety of HSK16149 capsules in Chinese Postherpetic Neuralgia Following 12 Weeks Treatment in Comparison to Placebo
Conditions
- Postherpetic Neuralgia
Interventions
HSK16149 20mg BIDDrug
HSK16149 20mg, orally twice a day, treatment period; 12-weeks fixed dose
HSK16149 40mg BIDDrug
HSK16149 40mg, orally twice a day, treatment period; 12-weeks fixed dose
Placebo BIDDrug
Placebo, orally twice a day, treatment period; 12-weeks fixed dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Compare the change from baseline in ADPS between HSK16149 and placebo at week 12Time frame: Baseline and week 12
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Dermatology Hospital of Chinese Academy of Medical Sciences
Nanjing, Jiangsu, China
The First Affiliated Hospital Of Nanchang University
Nanchang, Jiangxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.